Oncology Vol 33 No 5

This review summarizes the current evidence supporting the use of SBRT as treatment for inoperable renal cell carcinoma, as well as provides recommendations for patient selection and reviews the technical aspects of treatment and the expected toxicities.

In this case report, we present a non-Hodgkin lymphoma survivor who was incidentally found to have non–small-cell lung cancer 30 years after undergoing treatment that included mantle radiation. We discuss the treatment-related risk factors for lung cancer in this population and potential implications for long-term follow-up.

Dr. Sinicrope reviews the phase III ATOMIC trial, which is testing standard chemotherapy alone or in combination with the anti–PD-L1 antibody atezolizumab as adjuvant therapy in a subset of colon cancer patients.

This article reviews the current state of cancer research around the world.

In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.

This case looks at an otherwise healthy 59-year-old man who was recently diagnosed with clinical stage IVB prostate adenocarcinoma. What is the most appropriate management for this patient?

In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.